Many life science professionals encounter
opportunities to join start-ups. As well documented in
the industry's history, early stage ventures can be
successful and financially rewarding, challenging, or
catastrophic failures. How do you know if joining a
start-up is the right move for you? What are the key
points to evaluate when considering joining a
start-up? Our panel of seasoned life science
professionals will share what they have learned from
their experiences.
Specific topics will include:
Networking and light dinner from 6:30pm, plus networking session will follow.
Moderator:
Linda De Young, Ph.D., has led drug development at
multiple startup companies and has drug development
experience from big pharma, large biotech, early stage
drug delivery and early stage biotech companies
(Syntex, Genentech, AeroGen, Angiogenix and Threshold
Pharmaceuticals). She has built and led development
departments and project teams and has hands-on
experience managing programs in all major non-clinical
technical areas. Having joined Angiogenix and
Threshold as the second employee and AeroGen as the
first scientist, her development strategy has been to
do whatever is required to move a company forward,
from hiring cleaning staff, to hands-on lab work,
health and safety, managing outsourced projects, and
strategic planning. She is currently President of IND
Enabling Consulting, providing hands-on and strategic
drug development expertise to early stage companies
and project management to companies of all stages.
Presenters:
Linda DeYoung, President, IND Enabling Consulting
|
Peter Myers, Consultant/Chairman of Queensland
Biocapital Fund Science Advisory Board
|
|
|
Prior to his current position, Dr. Myers was most
recently Chief Executive Officer of Libraria, Inc.
(now Sertanty). Previously, Dr Myers served as
Executive VP and Site Director of Deltagen Research
Laboratories, as well as Chief Operating Officer/Chief
Scientific Officer of CombiChem, Inc. Under Dr. Myers'
scientific leadership, CombiChem established eight
major partnerships with companies such as Roche,
Sumitomo, Ono and Novartis and achieved significant
financial milestones in several of these
collaborations. He participated in the company's
public offering in 1998. Dr. Myers also served as VP
of Drug Discovery and Development at Onyx
Pharmaceuticals where he initiated their small
molecule Raf kinase program with Bayer. Before Onyx,
he served as VP of Chemistry Research at the Glaxo
Research Institute in Research Triangle, North
Carolina, where he managed over 100 personnel in
Medicinal Chemistry and Structure-based Drug Design.
He also served as Worldwide Therapeutic Head for all
of Glaxo's Inflammation Research and Deputy Chairman
for Cancer Research from 1991-2, and in 1993 assumed
worldwide responsibility for Glaxo's new therapeutic
area of Metabolic Diseases.
Dr. Myers previously served as Director of Medicinal
Chemistry for Glaxo Group Research and Director of
Chemistry at G.D. Searle & Co. Ltd. His first
position in the Healthcare Industry was for Reckitt &
Colman Plc, rising from to Chief Medicinal Chemist.
Dr. Myers has approximately 90 publications and
patents. He received his Doctorate in Organic
Chemistry and B.Sc. degree from Leeds University, in
England, where he was awarded the prize for best
thesis in 1967 and where he was subsequently a
Post-Doctoral Fellow.
|
|
|
Reynaldo Quintana, Director of Device Engineering,
Alexza MDC
|
|
|
Reynaldo is Director of Device Engineering at Alexza,
MDC where he is responsible for device development of
a pulmonary drug delivery systems to enable systematic
delivery of various compounds. Reynaldo has over 15
years experience in the medical device industry.
Prior to Alexza MDC, Reynaldo worked at Revivant
Corporation where he led the mechanical design of
Revivant's clinical prototype as well as a portion of
the commercial product. Reynaldo also worked at IDEO
Product Development, consulting on mechanical design
and product development for various medical devices,
including dental and diagnostic equipment.
Reynaldo received an undergraduate degree in
Mechanical Engineering from the University of Maryland
and a Master of Science in Biomedical Engineering from
Catholic University of America.
|
|
|
Gary W. Cleary, co-founder, President,
and Chief Technology Officer of Corium International, Inc.
|
|
|
Dr. Gary W. Cleary is an internationally recognized
scientist in the field of drug delivery systems and
polymer technologies. He is a co-founder, President,
and Chief Technology Officer of Corium International,
Inc. Corium (http://www.coriumtech.com) is a drug
delivery company that develops and manufactures
pharmaceutical and biotech products for delivery
through the skin & mucosa.
He holds 25 issued US patents with several pending
related to transdermal, mucosal, polymer science and
other drug delivery technologies. In 1991, he
received the Entrepreneur of the Year Award in Life
Sciences for Northern California and more recently,
the 2004 Biomaterials Entrepreneur Award of the New
Jersey Center for Biomaterials.
Dr. Cleary earned a Pharm.D. from UCSF, an MBA in
health sciences from the University of Miami, and a
Ph.D. in pharmaceutics from Rutgers University. He has
held research and management positions at the FDA,
Alza Corporation, Key Pharmaceuticals, Genentech, and
Cygnus, a company that developed the Ortho-Evra Patch
and GlucoWatch. Cleary founded Cygnus in 1985 and had
served as President, Chairman, and Chief Technical
Officer.
Cleary is a Fellow of the American Association of
Pharmaceutical Scientists (AAPS) and the American
Institute of Medical and Biomedical Engineering
(AIMBE) and past president of the Controlled Release
Society (CRS). He is a board member of charitable
organizations, government, academic and industrial
institutions. This year he co-authored the Drug
Delivery Section in .The Roadmap for Military
Medicine., a publication of the National Academy of
Sciences.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
